PMID- 24504989
OWN - NLM
STAT- MEDLINE
DCOM- 20150413
LR  - 20171116
IS  - 1578-2735 (Electronic)
IS  - 1139-9287 (Linking)
VI  - 42
IP  - 1
DP  - 2014 Jan-Feb
TI  - [Prevalence of metabolic syndrome in Spanish patients with schizophrenia and 
      overweight. The CRESSOB Study].
PG  - 9-17
AB  - INTRODUCTION: Metabolic syndrome (MS) (visceral obesity, dyslipidemia, 
      hyperglycemia, and hypertension), has become one of the major public-health 
      challenges worldwide. Patients with schizophrenia are more likely to suffer from 
      MS than the general population. OBJECTIVE: The primary aim of this study was to 
      analyze the prevalence of MS in Spanish patients with schizophrenia and 
      overweight and to compare the best method to calculate the MS prevalence in this 
      population. A secondary aim of the CRESSOB study was to determine whether the 
      presence of the metabolic syndrome (MS) is associated or not with clinical 
      remission of schizophrenia. METHODS: The Control of Metabolic and Cardiovascular 
      Risk in Patients with Schizophrenia and Overweight (CRESSOB) study is a 12-month, 
      prospective, naturalistic study including 110 community mental health clinics 
      selected at random. Each site enrolled four consecutive patients with a diagnosis 
      of schizophrenia, according to DSM-IV TR criteria, and who were overweight (Body 
      Mass Index (BMI) >25 kg/m2). To assess the prevalence of MS we analyzed the 
      baseline results of the CRESSOB study. The National Cholesterol Education Program 
      (NCEP-ATP III), the International Diabetes Federation (IDF) and the American 
      Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI) 
      definitions were used to establish the presence of MS. The Positive and Negative 
      Syndrome Scale (PANSS) was used to determine the percentage of patients in 
      remission. Psychosocial functioning was measured by the Global Assessment of 
      Functioning (GAF) scale. RESULTS: A total of 391 patients were enrolled in the 
      study (mean age 40.5 years, 63.8% men). 75.9% of the patients did not meet 
      criteria for remission, using the selected PANSS items. The mean GAF score was 
      52.7 (Standard Deviation (SD) 15.4). Overall, 59.0% of males and 58.3% of females 
      fulfilled the NCEP-ATP III criteria, 71.1% of males and 65.8% of females 
      fulfilled the IDF criteria and 70.1% of males and 65.1% of females fulfilled the 
      AHA/ NHLBI criteria. The patients who fulfilled remission criteria were younger, 
      had a lower BMI, and a higher GAF score. CONCLUSIONS: MS is highly prevalent in 
      Spanish patients with schizophrenia who are overweight. Given that metabolic 
      syndrome is an important risk factor for cardiovascular disease, these patients 
      should receive appropriate clinical monitoring for this syndrome.
FAU - Gutierrez-Rojas, Luis
AU  - Gutierrez-Rojas L
AD  - Psychiatry Service, San Cecilio University Hospital. CTS-549 Research Group, 
      Institute of Neurosciences, Center for Biomedical Research (CIBM), University of 
      Granada, Granada, Spain.
FAU - Azanza, Jose R
AU  - Azanza JR
AD  - Clinical Investigation Unit, University Hospital, University of Navarra, 
      Pamplona, Navarra, Spain.
FAU - Bernardo, Miquel
AU  - Bernardo M
AD  - Institut d Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, 
      Spain. Centro de Investigacion Biomedica en Red de Salud Mental (CIBERSAM), 
      Spain. Psychiatry Department, Hospital Clinic de Barcelona, Barcelona, Spain. 
      Department of Psychiatry & Clinical Psychobiology, University of Barcelona, 
      Barcelona, Spain.
FAU - Rojo, Luis
AU  - Rojo L
AD  - Psychiatric Unit, Hospital La Fe, Valencia, Spain.
FAU - Mesa, Francisco
AU  - Mesa F
AD  - Department of Neurosciences, Medical Unit, Pfizer Espana, Alcobendas, Madrid, 
      Spain.
FAU - Martinez-Ortega, Jose M
AU  - Martinez-Ortega JM
AD  - CTS-549 Research Group, Institute of Neurosciences, Center for Biomedical 
      Research (CIBM), University of Granada, Granada, Spain.
LA  - spa
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TT  - Prevalencia del sindrome metabolico en pacientes espanoles con esquizofrenia y 
      sobrepeso. El estudio CRESSOB.
DEP - 20140101
PL  - Spain
TA  - Actas Esp Psiquiatr
JT  - Actas espanolas de psiquiatria
JID - 100886502
SB  - IM
MH  - Adult
MH  - Female
MH  - Humans
MH  - Male
MH  - Metabolic Syndrome/*complications/*epidemiology
MH  - Middle Aged
MH  - Overweight/*complications
MH  - Prevalence
MH  - Prospective Studies
MH  - Risk Factors
MH  - Schizophrenia/*complications
MH  - Spain/epidemiology
EDAT- 2014/02/08 06:00
MHDA- 2015/04/14 06:00
CRDT- 2014/02/08 06:00
PHST- 2014/01/01 00:00 [received]
PHST- 2014/01/01 00:00 [accepted]
PHST- 2014/02/08 06:00 [entrez]
PHST- 2014/02/08 06:00 [pubmed]
PHST- 2015/04/14 06:00 [medline]
PST - ppublish
SO  - Actas Esp Psiquiatr. 2014 Jan-Feb;42(1):9-17. Epub 2014 Jan 1.